Hepatocellular Carcinoma Clinical Trial
Official title:
The Association of Liver Disease With Other Systemic Diseases, Focus on Diseases Progression, Treatments, and Clinical Outcomes: Analyses From the Hospital Database of Buddhist Tzu Chi Medical Foundation
Examine the association of chronic liver diseases (including hepatitis B, hepatitis C, alcoholic liver disease, fatty liver, liver cirrhosis, and hepatocellular carcinoma) with other systemic diseases by retrospectively analyzing the data from the Hospital Database of Buddhist Tzu Chi Medical Foundation.
The global population is growing older over the next several decades. An essential component
to keep people healthy, even with aging, is to prevent chronic disease progression and reduce
associated complications. About 80% of older adults have one chronic condition, and 50% have
at least two chronic disorders. Efforts to identify strategies to prevent or reduce the risk
of chronic diseases and injuries and to widely apply effective interventions must be pursued.
Because the liver is the largest solid organ in the human body with multiple functions,
including nutrition, metabolism, proteins and biochemicals synthesis, and detoxification, its
function is vital for the homeostasis of our body. The impairment of liver function may cause
dysfunction or even shut down other systems in our body. Therefore, a better understanding of
the pathogenesis of the liver disorder is not only a key issue in medical science, but it may
also affect the general health and diseases of other body systems in a variety of ways.
Finally, causing significant public health and economic losses globally. However, the impact
and interactions of liver disorders on the progression, treatments, and prognosis of other
systemic disorders, or vice versa, remain largely unknown. Recent studies have demonstrated
the interactions between diabetes mellitus and liver diseases, and implying a possible
deteriorating effect of diabetes on liver disease progression, treatment outcomes, and
hepatic carcinogenesis. These lines of evidence not only verify the need for a better
understanding of the interactions between liver and other disorders, but also justify a more
extensive exploration of the interactions between liver diseases and other systemic
disorders.
In this study, the investigators aim to examine the association of chronic liver diseases
(including hepatitis B, hepatitis C, alcoholic liver disease, fatty liver, liver cirrhosis
and hepatocellular carcinoma) with other systemic diseases by retrospectively analyzing the
data from the Hospital Database of Buddhist Tzu Chi Medical Foundation. The investigators
will examine the impacts of different systemic diseases on the disease progression and
prognosis of Taiwanese patients with liver diseases and vice versa. Moreover, the
investigators will also examine the different therapeutic strategies (including western,
traditional Chinese medical, surgical or varied treatments) used for the treatments of liver
diseases or systemic diseases, and their effects on the disease progression, long-term
outcomes and prognosis of patients with chronic liver diseases or other systemic diseases in
Taiwan.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |